Inspiring New Approaches

At Halozyme, we are focused on new and proven therapeutic approaches. We are driven to bring innovative and disruptive solutions and support to partners with a goal of significantly improving patient experiences, and potentially outcomes, for emerging and established therapies.

Our Focus

Our commercially validated ENHANZE® drug delivery technology, based on our proprietary enzyme rHuPH20, is used to facilitate the delivery of injected drugs and fluids. When co-formulated with other drugs, ENHANZE® has the potential to reduce treatment burden for patients, including potentially reducing treatment administration from hours-long IV infusions to SC injections delivered in minutes.

We are currently advancing multiple programs intended to deliver innovative therapies through world class collaborations. Our ENHANZE® technology has been licensed globally to leading pharmaceutical and biotechnology companies including, AbbVie, Alexion, argenx, Baxalta, Bristol-Myers Squibb, Horizon Therapeutics, Janssen, Lilly, Pfizer, Roche and ViiV Healthcare.

In addition, we market and commercialize Hylenex® recombinant (hyaluronidase human injection) in the United States, which is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs.

Commitment to ESG

We are committed to achieving our goal of improving patients’ lives while operating in a sustainable, socially responsible manner. This commitment is consistent with our core values, which provide us with a framework for how we can deliver benefits for patients, employees, the environment and local communities.


Our values unite us at Halozyme. As we relentlessly work toward our mission of improving patient experiences and outcomes, these values represent the core of each and every one of our team members.

We Respect and Value the Team

  • We work together and help each other achieve common goals.
  • We reward significant contributions and hire, develop and recognize talent that share our values.
  • We value each other’s opinion and disagree with each other respectfully.
  • We are committed to openness, respect and trust in our relationships.

We Focus on Patients

  • We are committed to providing patients with safe and effective therapies.
  • We work with our partners to help design products that optimize the patient experience.
  • We positively impact the lives of patients and their families.

We Do the Right Thing

  • We act with integrity and honesty to uphold the highest ethical standards.
  • We take pride in the quality of our work and our relationships.
  • We contribute to society and human welfare through the responsible development of our products.

We Are All Empowered and Accountable

  • We make fact-based, informed decisions and are enabled to set, prioritize and meet goals.
  • We are flexible and work together to overcome unforeseen events.
  • We fulfill our commitments to patients, partners, shareholders and each other.

We Innovate

  • We address gaps and weaknesses with unique and efficient solutions.
  • We improve processes and reduce costs without sacrificing quality.

Leadership Team

Helen Torley, M.B. Ch. B., M.R.C.P.

President and Chief Executive Officer

Mark Snyder

General Counsel, Chief Compliance Officer and Corporate Secretary

Nicole LaBrosse

Chief Financial Officer

Michael J. LaBarre, Ph.D.

Chief Technical Officer

Greg DeFilippis

Chief Business Officer

Steve Knowles, MB.BS, M.R.C.P., M.F.P.M.

Chief Medical Officer

Christopher Bryant, Ph.D.

Chief Manufacturing Officer and Head of Technical Operations

Kristin Schwartzbauer

Head of Quality

Tram Bui

Head of Investor Relations and Corporate Communications

Joe Renda

Head of Commercial

Amy Fox

Chief Human Resources Officer

Board of Directors

Jeffrey W. Henderson

Chair of the Board

Helen Torley, M.B. Ch. B., M.R.C.P.

President and Chief Executive Officer